This panel of three cardiac markers enhances the reliability of earlier identification and risk stratification of patients presenting with chest pain compared to a single marker (1,2). Measurements of cardiac protein markers are essential for the accurate diagnosis of acute coronary syndrome in the absence of well-defined electrocardiographic ST-segment elevations (3,4).
From a population of 224 individuals, the IB10 sphingotest® 3-in-1 Cardiac was used to determine the concentration upper reference limits of cTnI, CK-MB and Myoglobin. This population included apparently healthy individuals.
|cTnI||0.10 ng/mL (99th reference percentile)|
|CK-MB||8.58 ng/mL (95th reference percentile)|
|Myoglobin||99.84 ng/mL (95th reference percentile)|
Each laboratory should establish a reference range that represents the patient population that is to be evaluated at their facility.
Whole Blood vs. Plasma Comparison
All our assays correlate with r=0.9. For more detailed information please read the IFUs or connect with our sales representatives.
(1) Fan J et al. Clinical Value of Combined Detection of CK-MB, MYO, cTnI and Plasma NT-proBNP in Diagnosis of Acute Myocardial Infarction. Clin Lab. 2017 Mar 1;63(3):427-433.
(2) Newby LK et al. Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation. 2001 Apr 10;103(14):1832-7.
(3) Reichlin T et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation. 2011 Jul 12;124(2):136-45.
(4) Thygesen K et al. Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007 Nov 27;50(22):2173-95.